In the originally published article there was an error in Table 1. The reduction in monthly migraine days over 12 weeks versus placebo with quarterly fremanezumab was incorrectly given as “-0.6”; this should read “-3.7”.
Share this Article
Related Content In Headache Disorders
Potential Uses for Precision Tinted Lenses in a Neurology Clinic
touchREVIEWS in Neurology. 2022;18(2):93-102 DOI: https://doi.org/10.17925/USN.2022.18.2.93
Photophobia is a complex disorder that can involve aversion not simply to bright light but to spatial patterns, colour and flicker.1 It is common in neurological diseases that involve the visual system,2 of which migraine is the most prevalent. Tinted lenses have been widely advocated on the internet as a means of reducing photophobia, particularly in migraine, […]
Neuromodulation for Prevention and Treatment of Headache Disorders
touchREVIEWS in Neurology. 2022;18(2):103–8 DOI: https://doi.org/10.17925/USN.2022.18.2.103
Neuromodulation is a recent technique that has increasingly been used for the abortive and preventive treatment of migraine and other primary headache disorders.1 It has previously been found to be helpful in the treatment of other neurological illnesses, such as epilepsy.2 Neuromodulation treatment of headache disorders involves pain relief via manipulation of the peripheral or central pain […]
The UK’s Migraine Healthcare System: Key Problems and How They Can be Addressed
touchREVIEWS in Neurology. 2022;18(1):5–6 DOI: https://doi.org/10.17925/USN.2022.18.1.5
For a condition as highly prevalent and debilitating as migraine, there is still too little awareness of it and the impact it has. There is little understanding of the different symptoms and stages of a migraine attack, the frequency with which many people have migraine attacks and how this affects different aspects of their lives. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!